Gene transfer of mutant O6-methylguanine-DNA-methyltransferase (MGMTP140K) into hematopoietic stem cells (HSCs) protects hematopoiesis from alkylating agents and allows efficient in vivo selection of transduced HSCs. However, insertional mutagenesis, high regenerative stress associated with selection, and the genotoxic potential of alkylating drugs represent considerable risk factors for clinical applications of this approach. Therefore, we investigated the long-term effect of MGMTP140K gene transfer followed by repetitive, dose-intensive treatment with alkylating agents in a murine serial bone marrow transplant model and assessed clonality of hematopoiesis up to tertiary recipients. The substantial selection pressure resulted in almost completely transduced hematopoiesis in all cohorts. Ligation-mediated PCR and next-generation sequencing identified several repopulating clones carrying vector insertions in distinct genomic regions that were ∼9 kb of size (common integration sites). Beside polyclonal reconstitution in the majority of the mice, we also detected monoclonal or oligoclonal repopulation patterns with HSC clones showing vector insertions in the Usp10 or Tubb3 gene. Interestingly, neither Usp10, Tubb3, nor any of the genes located in common integration sites have been linked to clonal expansion in previous preclinical or clinical gene therapy trials. However, a considerable number of these genes are involved in DNA damage response and cell fate decision pathways following cytostatic drug application. Thus, in summary, our study advocates ligation-mediated PCR and next generation sequencing as an effective and reliable method to identify gene products associated with clonal survival in specific experimental settings such as chemoselection using alkylating agents.
Get full access to this article
View all access options for this article.
References
1.
AbkowitzJ.L., CatlinS.N., McCallieM.T., GuttorpP.2002. Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. Blood, 100:2665–2667.
2.
AiutiA., CattaneoF., GalimbertiS.et al.2009. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med., 360:447–458.
3.
AiutiA., SlavinS., AkerM.et al.2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 296:2410–2413.
4.
AppeltJ.U., GiordanoF.A., EckerM.et al.2009. QuickMap: a public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Ther., 16:885–893.
5.
BallC.R., PilzI.H., SchmidtM.et al.2007. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression. Blood, 110:1779–1787.
6.
BaumC.2007. Insertional mutagenesis in gene therapy and stem cell biology. Curr. Opin. Hematol., 14:337–342.
7.
BaumC., KustikovaO., ModlichU.et al.2006. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum. Gene Ther., 17:253–263.
8.
BeardB.C., SudR., KeyserK.A.et al.2009. Long-term polyclonal and multilineage engraftment of MGMTP140K gene-modified dog hematopoietic cells in primary and secondary recipients. Blood, 113:5094–5103.
9.
BierhuizenM.F., WestermanY., VisserT.P.et al.1997. Enhanced green fluorescent protein as selectable marker of retroviral-mediated gene transfer in immature hematopoietic bone marrow cells. Blood, 90:3304–3315.
10.
BinladenJ., GilbertM.T., BollbackJ.P.et al.2007. The use of coded PCR primers enables high-throughput sequencing of multiple homolog amplification products by 454 parallel sequencing. PLoS ONE, 2:e197.
11.
BleierS., MaierP., AllgayerH.et al.2008. Multiple displacement amplification enables large-scale clonal analysis following retroviral gene therapy. J. Virol., 82:2448–2455.
12.
BozorgmehrF., LaufsS., SellersS.E.et al.2007. No evidence of clonal dominance in primates up to 4 years following transplantation of multidrug resistance 1 retrovirally transduced long-term repopulating cells. Stem Cells, 25:2610–2618.
13.
BoztugK., SchmidtM., SchwarzerA.et al.2010. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med., 363:1918–1927.
14.
Budak-AlpdoganT., BanerjeeD., BertinoJ.R.2005. Hematopoietic stem cell gene therapy with drug resistance genes: an update. Cancer Gene Ther., 12:849–863.
15.
CalmelsB., FergusonC., LaukkanenM.O.et al.2005. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood, 106:2530–2533.
16.
CartierN., Hacein-Bey-AbinaS., BartholomaeC.C.et al.2009. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326:818–823.
17.
CattoglioC., FacchiniG., SartoriD.et al.2007. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood, 110:1770–1778.
18.
Cavazzana-CalvoM., PayenE., NegreO.et al.2010. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature, 467:318–322.
19.
ChenX., ZhuH., YuanM.et al.2010. G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA damage-induced apoptosis. J. Biol. Chem., 285:12823–12830.
ClopperC.J., PearsonE.S.1934. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika, 26:404–413.
22.
DavisB.M., ReeseJ.S., KocO.N.et al.1997. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res., 57:5093–5099.
23.
DeichmannA., Hacein-Bey-AbinaS., SchmidtM.et al.2007. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest., 117:2225–2232.
24.
DolanM.E., MoschelR.C., PeggA.E.1990. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. U. S. A., 87:5368–5372.
25.
DykstraB., KentD., BowieM.et al.2007. Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell, 1:218–229.
FlasshoveM., BardenheuerW., SchneiderA.et al.2000. Type and position of promoter elements in retroviral vectors have substantial effects on the expression level of an enhanced green fluorescent protein reporter gene. J. Cancer Res. Clin. Oncol., 126:391–399.
28.
GabrielR., EckenbergR., ParuzynskiA.et al.2009. Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med., 15:1431–1436.
29.
GerritsA., DykstraB., KalmykowaO.J.et al.2010. Cellular barcoding tool for clonal analysis in the hematopoietic system. Blood, 115:2610–2618.
30.
GersonS.L.2000. Drug resistance gene transfer: Stem cell protection and therapeutic efficacy. Exp. Hematol., 28:1315–1324.
31.
GersonS.L., PhillipsW., KastanM.et al.1996. Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. Blood, 88:1649–1655.
32.
GerullS., BeardB.C., PetersonL.J.et al.2007. In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum. Gene Ther., 18:451–456.
33.
GiordanoF.A., Hotz-WagenblattA., LauterbornD.et al.2007. New bioinformatic strategies to rapidly characterize retroviral integration sites of gene therapy vectors. Methods Inf. Med., 46:542–547.
34.
Hacein-Bey-AbinaS., GarrigueA., WangG.P.et al.2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118:3132–3142.
35.
Hacein-Bey-AbinaS., Le DeistF., CarlierF.et al.2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med., 346:1185–1193.
36.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM.et al.2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302:415–419.
37.
HoweS.J., MansourM.R., SchwarzwaelderK.et al.2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 118:3143–3150.
38.
JansenM., SorgU.R., RaggS.et al.2002. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther., 9:737–746.
39.
KavallarisM., KuoD.Y., BurkhartC.A.et al.1997. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest., 100:1282–1293.
40.
KustikovaO., FehseB., ModlichU.et al.2005. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science, 308:1171–1174.
41.
LaufsS., GentnerB., NagyK.Z.et al.2003. Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood, 101:2191–2198.
MilsomM., SchambachA., WilliamsD.A., BaumC.2008. Chemoprotective gene delivery. Viral Therapy of Cancer. HaringtonK.J., VileR.G., PandhaH.S.Wiley Press: Indianapolis, IN, 377–391.
45.
ModlichU., KustikovaO.S., SchmidtM.et al.2005. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood, 105:4235–4246.
46.
MoritzT., WilliamsD.A.2001. Marrow protection—transduction of hematopoietic cells with drug resistance genes. Cytotherapy, 3:67–84.
47.
MozzettiS., IantomasiR., De MariaI.et al.2008. Molecular mechanisms of patupilone resistance. Cancer Res., 68:10197–10204.
48.
Muller-SieburgC.E., ChoR.H., ThomanM.et al.2002. Deterministic regulation of hematopoietic stem cell self-renewal and differentiation. Blood, 100:1302–1309.
49.
NagyK.Z., LaufsS., GentnerB.et al.2004. Clonal analysis of individual marrow-repopulating cells after experimental peripheral blood progenitor cell transplantation. Stem Cells, 22:570–579.
50.
NeffT., BeardB.C., PetersonL.J.et al.2005. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood, 105:997–1002.
51.
NeffT., HornP.A., PetersonL.J.et al.2003. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J. Clin. Invest., 112:1581–1588.
52.
OttM.G., SchmidtM., SchwarzwaelderK.et al.2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med., 12:401–409.
53.
PeggA.E.1990. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res., 50:6119–6129.
54.
PeggA.E., BoosalisM., SamsonL.et al.1993. Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. Biochemistry, 32:11998–12006.
55.
RaggS., Xu-WelliverM., BaileyJ.et al.2000. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res., 60:5187–5195.
56.
RoederI., HornK., SieburgH.B.et al.2008. Characterization and quantification of clonal heterogeneity among hematopoietic stem cells: a model-based approach. Blood, 112:4874–4883.
57.
SawaiN., ZhouS., VaninE.F.et al.2001. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol. Ther., 3:78–87.
58.
SchiedlmeierB., SchilzA.J., KuhlckeK.et al.2002. Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice. Hum. Gene Ther., 13:233–242.
59.
SeggewissR., PittalugaS., AdlerR.L.et al.2006. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood, 107:3865–3867.
60.
SteenH., LindholmD.2008. Nuclear localized protein-1 (Nulp1) increases cell death of human osteosarcoma cells and binds the X-linked inhibitor of apoptosis protein. Biochem. Biophys. Res. Commun., 366:432–437.
61.
SteinS., OttM.G., Schultze-StrasserS.et al.2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med., 16:198–204.
62.
StengelC., NewmanS.P., LeeseM.P.et al.2009. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br. J. Cancer, 102:316–324.
63.
WangG.P., CiuffiA., LeipzigJ.et al.2007. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res., 17:1186–1194.
64.
WangG.P., GarrigueA., CiuffiA.et al.2008. DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res., 36:e49.
65.
Xu-WelliverM., KanugulaS., PeggA.E.1998. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine. Cancer Res., 58:1936–1945.
66.
YamazakiS., NakauchiH.2009. Insights into signaling and function of hematopoietic stem cells at the single-cell level. Curr. Opin. Hematol., 16:255–258.
67.
YuanJ., LuoK., ZhangL.et al.2010. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell, 140:384–396.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
